Literature DB >> 11860230

CD52 (CAMPATH1).

G Hale1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11860230

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN： 0393-974X            Impact factor:   1.711


× No keyword cloud information.
  11 in total

1.  Immune regulation by CD52-expressing CD4 T cells.

Authors:  Ban-Hock Toh; Tin Kyaw; Peter Tipping; Alex Bobik
Journal:  Cell Mol Immunol       Date:  2013-08-12       Impact factor: 11.530

2.  CD52 inhibits Toll-like receptor activation of NF-κB and triggers apoptosis to suppress inflammation.

Authors:  Maryam Rashidi; Esther Bandala-Sanchez; Kate E Lawlor; Yuxia Zhang; Alana M Neale; Swarna L Vijayaraj; Robert O'Donoghue; John M Wentworth; Timothy E Adams; James E Vince; Leonard C Harrison
Journal:  Cell Death Differ       Date:  2017-12-15       Impact factor: 15.828

3.  T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10.

Authors:  Esther Bandala-Sanchez; Yuxia Zhang; Simone Reinwald; James A Dromey; Bo-Han Lee; Junyan Qian; Ralph M Böhmer; Leonard C Harrison
Journal:  Nat Immunol       Date:  2013-05-19       Impact factor: 25.606

4.  Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.

Authors:  Yanping Hu; Michael J Turner; Jacqueline Shields; Matthew S Gale; Elizabeth Hutto; Bruce L Roberts; William M Siders; Johanne M Kaplan
Journal:  Immunology       Date:  2009-10       Impact factor: 7.397

5.  Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis.

Authors:  Sambasiva P Rao; Jose Sancho; Juanita Campos-Rivera; Paula M Boutin; Peter B Severy; Timothy Weeden; Srinivas Shankara; Bruce L Roberts; Johanne M Kaplan
Journal:  PLoS One       Date:  2012-06-25       Impact factor: 3.240

6.  Effect of alemtuzumab on intestinal intraepithelial lymphocytes and intestinal barrier function in cynomolgus model.

Authors:  Lin-Lin Qu; Ya-Qing Lyu; Hai-Tao Jiang; Ting Shan; Jing-Bin Zhang; Qiu-Rong Li; Jie-Shou Li
Journal:  Chin Med J (Engl)       Date:  2015-03-05       Impact factor: 2.628

7.  Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation.

Authors:  C B Resende; B M Rezende; P T T Bernardes; G M Teixeira; M M Teixeira; V Pinho; H Bittencourt
Journal:  Braz J Med Biol Res       Date:  2017-02-09       Impact factor: 2.590

8.  Effect of anti-CD52 antibody alemtuzumab on ex-vivo culture of umbilical cord blood stem cells.

Authors:  Che K Lim; Li Sun; Qi Feng; Ping Law; Wei T Chua; Shy N Lim; William Y K Hwang
Journal:  J Hematol Oncol       Date:  2008-10-23       Impact factor: 17.388

9.  CD52 glycan binds the proinflammatory B box of HMGB1 to engage the Siglec-10 receptor and suppress human T cell function.

Authors:  Esther Bandala-Sanchez; Naiara G Bediaga; Ethan D Goddard-Borger; Katrina Ngui; Gaetano Naselli; Natalie L Stone; Alana M Neale; Lesley A Pearce; Ahmad Wardak; Peter Czabotar; Thomas Haselhorst; Andrea Maggioni; Lauren A Hartley-Tassell; Timothy E Adams; Leonard C Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-11       Impact factor: 11.205

Review 10.  Laboratory studies for paroxysmal nocturnal hemoglobinuria, with emphasis on flow cytometry.

Authors:  Margarida Lima
Journal:  Pract Lab Med       Date:  2020-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.